The generation and characterisation of antagonist RNA aptamers to MCP-1

被引:32
作者
Rhodes, A
Smithers, N
Chapman, T
Parsons, S
Rees, S
机构
[1] Glaxo Wellcome Res & Dev Ltd, Mol Discovery Dept, Stevenage SG1 2NY, Herts, England
[2] Glaxo Wellcome Res & Dev Ltd, Mol Recognit Dept, Stevenage SG1 2NY, Herts, England
[3] Glaxo Wellcome Res & Dev Ltd, In Vitro Pharmacol, Stevenage SG1 2NY, Herts, England
[4] Glaxo Wellcome Res & Dev Ltd, Dept Mol Pharmacol, Stevenage SG1 2NY, Herts, England
来源
FEBS LETTERS | 2001年 / 506卷 / 02期
关键词
aptamer; monocyte chemoattractant protein-1; proteomics; CCR2; inflammation;
D O I
10.1016/S0014-5793(01)02895-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Monocyte chemoattractant protein-1 (MCP-1) has been implicated as a powerful pro-inflammatory mediator and may represent a potentially important, therapeutic opportunity for treatment of inflammatory disease and atherosclerosis. To further investigate the role of MCP-1 in inflammatory disorders we have isolated a series of RNA aptamers that bind specifically to mouse MCP-1. The highest affinity aptamers, designated ADR7 and ADR22, have been functionally characterised in vitro and in cell based assays. ADR7 and ADR22 have an affinity of 180 pM and 370 pM respectively for mouse MCP-1, they can antagonise MCP-1 binding to heparin and specifically antagonise MCP-1 induced chemotaxis in a cell based assay. An interesting feature of ADR22 but not ADR7 is that it is capable of antagonising the function of human MCP-1, demonstrating the high level of specificity of these aptamers and that the aptamers recognise MCP-1 in different ways. The aptamers may be used as a tool to further investigate the role of MCP-1 in inflammatory disorders and may also have a role as a therapeutic agent. (C) 2001 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:85 / 90
页数:6
相关论文
共 37 条
[1]  
ADAMS SM, 1991, FOCUS, V13, P56
[2]   SELECTION OF SINGLE-STRANDED-DNA MOLECULES THAT BIND AND INHIBIT HUMAN THROMBIN [J].
BOCK, LC ;
GRIFFIN, LC ;
LATHAM, JA ;
VERMAAS, EH ;
TOOLE, JJ .
NATURE, 1992, 355 (6360) :564-566
[3]   MOLECULAR-CLONING AND FUNCTIONAL EXPRESSION OF 2 MONOCYTE CHEMOATTRACTANT PROTEIN-1 RECEPTORS REVEALS ALTERNATIVE SPLICING OF THE CARBOXYL-TERMINAL TAILS [J].
CHARO, IF ;
MYERS, SJ ;
HERMAN, A ;
FRANCI, C ;
CONNOLLY, AJ ;
COUGHLIN, SR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (07) :2752-2756
[4]   Controlling signaling with a specifically designed Gi-coupled receptor [J].
Coward, P ;
Wada, HG ;
Falk, MS ;
Chan, SDH ;
Meng, F ;
Akil, H ;
Conklin, BR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (01) :352-357
[5]  
Fitzwater T, 1996, METHOD ENZYMOL, V267, P275
[6]   Novel approach to specific growth factor inhibition in vivo -: Antagonism of platelet-derived growth factor in glomerulonephritis by aptamers [J].
Floege, J ;
Ostendorf, T ;
Janssen, U ;
Burg, M ;
Radeke, HH ;
Vargeese, C ;
Gill, SC ;
Green, LS ;
Janjic, N .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (01) :169-179
[7]   DIVERSITY OF OLIGONUCLEOTIDE FUNCTIONS [J].
GOLD, L ;
POLISKY, B ;
UHLENBECK, O ;
YARUS, M .
ANNUAL REVIEW OF BIOCHEMISTRY, 1995, 64 :763-797
[8]   An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model [J].
Gong, JH ;
Ratkay, LG ;
Waterfield, JD ;
ClarkLewis, I .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (01) :131-137
[9]   Inhibitory DNA ligands to platelet-derived growth factor B-chain [J].
Green, LS ;
Jellinek, D ;
Jenison, R ;
Ostman, A ;
Heldin, CH ;
Janjic, N .
BIOCHEMISTRY, 1996, 35 (45) :14413-14424
[10]   NUCLEASE-RESISTANT NUCLEIC-ACID LIGANDS TO VASCULAR-PERMEABILITY FACTOR VASCULAR ENDOTHELIAL GROWTH-FACTOR [J].
GREEN, LS ;
JELLINEK, D ;
BELL, C ;
BEEBE, LA ;
FEISTNER, BD ;
GILL, SC ;
JUCKER, FM ;
JANJIC, N .
CHEMISTRY & BIOLOGY, 1995, 2 (10) :683-695